ChrysCapital Group has acquired a minority stake in Linux Laboratories Private Limited, a Chennai-based pharmaceutical company. The ChrysCapital Linux Laboratories stake acquisition involved a dual-layered transaction structure combining secondary share purchases and a fresh primary subscription. Shardul Amarchand Mangaldas & Co acted as sole legal advisor to ChrysCapital Group on all legal aspects of the investment.
Introduction
Linux Laboratories, a Chennai-headquartered pharmaceutical formulations company, raised $70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III, in a transaction combining primary capital infusion and a secondary share purchase.
The transaction comprises a secondary acquisition of shares from the Promoters and Tata Capital Healthcare Fund II, and a primary subscription to shares proposed to be issued by the Target Company. The deal sees ChrysCapital acquiring a significant minority stake in Linux Laboratories and includes a full exit of Tata Capital Healthcare Fund II (TCHF II) at approximately 4x returns.
At the same time, the deal marks Tata Capital‘s reinvestment in the firm through its third healthcare-focused vehicle. For further deal tracking, see the Deal Meter.
Deal Value
Linux Laboratories raised $70 million in equity capital from ChrysCapital and Tata Capital Healthcare Fund III. The announcement, dated 29 September 2026, combines primary investment with a secondary share purchase; the precise primary-versus-secondary split was not disclosed.
Legal Teams Involved
Shardul Amarchand Mangaldas & Co advised ChrysCapital Group on all legal aspects of the investment.
Transaction Team:
- Karun Prakash (Partner)
- Sangamitra Sankaraiah (Partner)
- Simran Khullar (Senior Associate)
- Amrusha Monga (Senior Associate)
- Aradhana Parmeshwar (Associate)
Due Diligence Team:
- Karun Prakash (Partner)
- Sangamitra Sankaraiah (Partner)
- Pooja Ramchandani (Partner)
- Devaditya Chakravarti (Counsel)
- Suryansh Gupta (Principal Associate)
- Simran Khullar (Senior Associate)
- Aradhana Parmeshwar (Associate)
- Shivani Pattnaik (Associate)
- Aagam Jain (Associate)
- Faiz Ahmad (Associate)
- Shalini Prem (Associate)
Competition Law:
- Rohan Arora (Partner)
- Rahul Shukla (Principal Associate)
Significance and Impact
The transaction is intended to support Linux Laboratories‘ expansion across specialised pharmaceutical segments, accelerate brand acquisitions, and strengthen its manufacturing and research capabilities.
Tata Capital Healthcare Fund II (TCHF II), which had invested in Linux Laboratories for around five years, has fully exited at approximately four times its investment. The deal simultaneously marks Tata Capital‘s continued commitment to the company through its successor fund.
The transaction is also notable for its competition law dimension. Rohan Arora (Partner) and Rahul Shukla (Principal Associate) advised on competition law aspects, reflecting the regulatory scrutiny that private equity investments in the Indian pharmaceutical sector routinely attract. The breadth of the Shardul Amarchand Mangaldas & Co team — spanning transaction execution, multi-workstream due diligence, and competition law — underscores the complexity of the deal structure.
Shardul Amarchand Mangaldas & Co advised ChrysCapital Group on the acquisition of a minority stake in Linux Laboratories Private Limited, a Chennai-based pharmaceutical company. The $70 million transaction, structured as a combination of primary and secondary components, provides a full exit for Tata Capital Healthcare Fund II while simultaneously bringing in Tata Capital Healthcare Fund III as a reinvesting institutional backer. Further details on ownership percentages and the primary-secondary value split were not disclosed.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
